Ex-Sanofi CEO Viehbacher says kickback allegations 'baseless'; KKR invests in Arbor;

@FiercePharma: Reckitt CEO, nearing spinoff, thinks he can outdo Big Pharma in consumer health. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. Article | Follow @EricPFierce

> The FDA has issued guidance on how generic drugmakers can get sample of branded products from reluctant companies. Guidance

> Former Sanofi ($SNY) CEO Chris Viehbacher called allegations "baseless" in a whistleblower lawsuit that states the company paid $34 million in kickbacks to boost sales of its diabetes medicines. Story

> Private equity investor KKR says it has taken a substantial minority stake in Atlanta, GA-based Arbor Pharmaceuticals. Release

> The Centers for Disease Control says mutations in flu bugs may make this year's vaccines less effective. Story

Medical Device News

@FierceMedDev: Welch Allyn partners with LKC to distribute novel diabetic retinopathy device. Story | Follow @FierceMedDev

@EmilyWFierce: Covidien loses battle in patent war with J&J as top U.S. patent court throws out $176M award. More | Follow @EmilyWFierce

> Welch Allyn partners with LKC to distribute novel diabetic retinopathy device. News

> Covidien loses battle in patent war with J&J as top U.S. patent court throws out $176M award. More

> Congress looks to deflate Medicare coverage of penis pumps. Story

Biotech News

@FierceBiotech: Does the 'sharing economy' have a place in biotech? More | Follow @FierceBiotech

@JohnCFierce: $GSK news blew away the rest of the yr's top 10 reports in terms of readers. And it was all industry/investors. Story | Follow @JohnCFierce

@DamianFierce: Sorting through $PFE for $BMY tweets is like a survey course in the epidemiology of bio Twitter BS. Highly recommended. | Follow @DamianFierce

> Juno expands its CAR-T arsenal with latest immuno-oncology deal. News

> Does the 'sharing economy' have a place in biotech? Article

> U.K. biotech Evgen plots a $31M IPO to push its vegetable-derived pipeline. More

And Finally... 23andMe is offering its personal genetic testing service in the U.K., which it says, among other things, can tell consumers how they will respond to hepatitis C drugs and other medications. Release

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.